^
    Back
    Association details:
    Biomarker:BCL2 positive
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Polivy (polatuzumab vedotin-piiq) (Microtubule inhibitor, CD79b-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    439 Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit LymphomaClinically Relevant Abstract

    Published date:
    11/02/2023
    Excerpt:
    Response was evaluated in 30 pts, with an EOT PET-CT based objective response rate and CR of 86.7% (n=26; including all pts with DHL/THL [n=8; CR: 100%])... Ven 800mg/D for 5 Ds/cycle + Pola-R-CHP has been determined as the RP2D; early results show acceptable safety and promising efficacy for untreated BCL-2 IHC+ DLBCL. High CR rates were observed across all cohorts at EOT, including pts with DHL/THL.
    Secondary therapy:
    R-CHP
    Trial ID:
    BO42203